Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a buy rating and issued a $62.00 price target on shares of Acceleron Pharma in a report on Monday. Royal Bank of Canada initiated coverage on shares of Acceleron Pharma in a research note on Thursday, September 14th. They set a sector perform rating and a $44.00 price objective on the stock. UBS reissued a buy rating and set a $50.00 price objective (up previously from $36.00) on shares of Acceleron Pharma in a research note on Tuesday, September 12th. Cann reissued a hold rating on shares of Acceleron Pharma in a research note on Tuesday, September 5th. Finally, ValuEngine raised shares of Acceleron Pharma from a sell rating to a hold rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $44.56.
Shares of Acceleron Pharma (XLRN) opened at $37.65 on Monday. Acceleron Pharma has a fifty-two week low of $23.07 and a fifty-two week high of $40.35.
In related news, major shareholder Corp /De/ Celgene purchased 745,592 shares of the business’s stock in a transaction on Monday, September 25th. The shares were bought at an average price of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the purchase, the insider now directly owns 6,118,479 shares in the company, valued at approximately $226,383,723. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. GSA Capital Partners LLP purchased a new position in Acceleron Pharma during the third quarter worth approximately $1,496,000. Iguana Healthcare Management LLC purchased a new position in Acceleron Pharma during the third quarter worth approximately $2,612,000. Point72 Asset Management L.P. purchased a new position in Acceleron Pharma during the third quarter worth approximately $2,721,000. Granahan Investment Management Inc. MA raised its stake in Acceleron Pharma by 15.2% during the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock worth $8,102,000 after purchasing an additional 28,694 shares during the period. Finally, Perceptive Advisors LLC raised its stake in Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after purchasing an additional 905,000 shares during the period. 85.84% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Acceleron Pharma’s (XLRN) Hold Rating Reiterated at Oppenheimer” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://weekherald.com/2017/12/14/acceleron-pharmas-xlrn-hold-rating-reiterated-at-oppenheimer.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.